

FOR IMMEDIATE RELEASE:

**Michael J. Brownstein, M.D. Ph.D. Appointed Chief Scientific Officer of
Exponential Biotherapies, Inc.**

McLean, VA, May 2, 2007 – Dr. M.J. Brownstein has accepted the position of Chief Scientific Officer at EBI to oversee the company's research program in small physiologically active peptides. Dr. Brownstein brings over thirty years of research experience in the fields of endocrinology, pharmacology and genetics to the company's drug development program. With both his M.D. and Ph.D. degrees from the University of Chicago, Dr. Brownstein joined the National Institute of Health where he eventually became chief of the Laboratory of Genetics of the National Institute of Mental Health and the National Human Genome Research Institute. He has since then directed the functional genomics program at the J. Craig Venter Institute in Rockville, MD. In addition to his scientific career in which he has published more than 200 papers in peer reviewed journals, Dr. Brownstein has been a founder of several successful companies.

EBI is a privately held, McLean, Virginia based drug discovery and development company with a growing pipeline of novel small molecule drugs designed to treat a wide range of severe inflammatory disorders such as septic shock, radiation sickness and avian influenza. These compounds represent a new class of immune regulating therapeutic agents.

Forward-looking statements

This press release contains forward looking statements, including statements related to our clinical trials and product candidates. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these or other risks and uncertainties, which include, without limitation, risks as to the adequacy of the proceeds of the financing to satisfy our financial requirements; risks related to the progress, timing and results of clinical trials; risks that subsequent clinical trials may show our candidate compounds are not safe and/or effective; issues relating to the intellectual property upon which our drug candidates are dependent; difficulties or delays in obtaining regulatory approval or clearance which are necessary or advisable in the conduct of future clinical trials or are necessary for the commercialization of any of our product candidates; manufacturing issues relating to any of our drug candidates; our ability to obtain financial resources necessary to support our clinical trials, other operations and financial commitments; competitive issues; and other regulatory considerations which affect the business prospects of EBI. Given these and other uncertainties, you should not place undue reliance on these forward-looking statements.

Contact:

Zsolt Harsanyi, Ph.D., Chairman and CEO: 703-883-3701